Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

A2B543

Phase 2Biologic

AA2 Biotherapeutics Inc.

A2B543 is one of 48 biologic programs targeting Safety and Efficacy. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

47

Competitors

Pipeline

Status by Indication[3][1]

Indication

Safety and EfficacyRecruiting

Safety and EfficacyPhase 2

Recruiting

Competition

Competitive Landscape

130 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Avastin

Actemra

Humira

RRanbaxy Laboratories Limited

Rayos

RRoxane Laboratories

Empaveli

Apellis Pharmaceuticals

CAB LA

Cytosar

B/F/TAF

Selzentry

Nuzyra

PParatek Pharmaceuticals Inc

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1/2Recruiting

Safety and Efficacy

NCT06051695

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Recruiting·AA2 Biotherapeutics Inc.·Phase 1/2·NCT06051695·474 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for A2B543. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — A2B543 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for A2B543. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — A2 Biotherapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AA2 Biotherapeutics Inc.

Related News